Anzeige
Mehr »
Donnerstag, 25.06.2026 - Börsentäglich über 12.000 News
Die 0,61-CAD-Uranaktie, die den Giganten hinterherjagt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856625 | ISIN: JP3837800006 | Ticker-Symbol: HYB
Tradegate
24.06.26 | 20:27
142,00 Euro
-1,29 % -1,85
1-Jahres-Chart
HOYA CORPORATION Chart 1 Jahr
5-Tage-Chart
HOYA CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
142,20144,5024.06.
142,00143,9524.06.
PR Newswire
345 Leser
Artikel bewerten:
(2)

PENTAX Medical and FUJIFILM Corporation Renew Ultrasound Diagnostic Business Collaboration Agreement

TOKYO, June 4, 2026 /PRNewswire/ -- PENTAX Medical announced the renewal of their longstanding collaboration with FUJIFILM Corporation in the field of Endoscopic Ultrasound (EUS). Effective April 2026, the renewed agreement establishes a framework that reinforces the long-term cooperative relationship between the two companies, for the supply of ultrasound diagnostic equipment and related products.

The collaboration covers the ARIETTA 850, ARIETTA 750, and ARIETTA 65 ultrasound scanners, which are used in combination with PENTAX Medical's EUS-J10 and EB-J10 line of echoendoscopes as well as the INSPIRA video processor. Together, these integrated solutions have long been recognized as market leaders in Endoscopic Ultrasound, providing physicians with advanced visualization, precision, and access that are critical to successful patient outcomes.

Importantly, the renewed agreement ensures continuity and reliability for customers, with the ability to provide product support for over a decade, reinforcing PENTAX Medical commitments to long-term clinical confidence and investment protection for our customers.

With decades of experience in echoendoscope development and ultrasound imaging innovation, this collaboration delivers seamless system compatibility, dependable performance, and consistent clinical excellence. "We are excited to continue this long-term relationship, which allows PENTAX Medical to continue providing our valued customers with a world-class clinical experience," said Dominique Vincent, Global President of PENTAX Medical. "Our echoendoscopes are uniquely calibrated to work seamlessly with the ARIETTA ultrasound systems, and this agreement enables us to continue delivering integrated solutions that physicians trust-today and well into the future."

This milestone reflects PENTAX Medical's commitment to advancing next-generation echoendoscope technologies that will drive the evolution of Endoscopic Ultrasound, backed by a foundation of first-to-market-innovations, quality, and sustained customer support.

About PENTAX Medical

PENTAX Medical, a division of the HOYA Group, is a global player in flexible, reusable endoscopy solutions. The company develops, manufactures, distributes, and services endoscopic equipment worldwide. PENTAX Medical is committed to delivering intuitive, flexible endoscopy solutions that empower healthcare professionals to provide outstanding care. Its mission is to maintain product excellence while collaborating closely with clinical partners to understand and address their daily challenges, workflows, and goals. At the core of this mission is a commitment to reliability and high-quality imaging-fundamental requirements for clinical performance. Building on this foundation, PENTAX Medical delivers solutions that integrate seamlessly into clinical practice, supported by ergonomic and ease-of-use innovations, practical clinical education, and personalized, attentive customer support.
For more information, please visit our website: https://www.pentaxmedical.com

About HOYA

HOYA Corporation, founded in Tokyo in 1941, is a global leader in healthcare and technology innovation. HOYA provides advanced products for life care, including eyeglass lenses, intraocular lenses, and medical endoscopes, as well as high-precision components that support today's information society, such as mask blanks for semiconductor manufacturing, glass substrates for hard disk drives, and optical components for imaging systems. With over 150 offices worldwide and a team of around 38,000 professionals, HOYA is committed to advancing technologies that contribute to a more sustainable future. For more details, please visit our website (https://www.hoya.com/en/).

Cision View original content:https://www.prnewswire.co.uk/news-releases/pentax-medical-and-fujifilm-corporation-renew-ultrasound-diagnostic-business-collaboration-agreement-302790954.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.